Rize Oncology Inc. (CSE: RIZE)

Canada flag Canada · Delayed Price · Currency is CAD
0.100
0.00 (0.00%)
At close: Jan 17, 2025
150.00%
Market Cap 7.57M
Revenue (ttm) n/a
Net Income (ttm) -941.56K
Shares Out 75.74M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,000
Average Volume 5,670
Open 0.120
Previous Close n/a
Day's Range 0.100 - 0.120
52-Week Range 0.015 - 0.120
Beta 2.24
RSI 57.21
Earnings Date Mar 28, 2025

About Rize Oncology

Rize Oncology Inc., a pharmaceutical company, develops oncology therapies for the treatment of soft tissue sarcoma. The company develops STS-201, a small molecule drug candidate for the treatment of soft tissue sarcoma, as well as other types of cancers and proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada. [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol RIZE
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.